Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNAZ Trial: Zanubrutinib and Rituximab for IgM MGUS/anti-MAG Polyneuropathy
NCT05939037Phase 2Active, not recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib. Started Mar 2024; status: active, not recruiting.
02
Drugs
zanubrutinib
Beyond the preview
Go deeper on NCT05939037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939037.